exRNAdisease

General Information

Database ID:

exR0084928

RNA Name:

ZNF354B

RNA Type:

mRNA

Chromosome:

chr5

Starnd:

Coordinate:

Start Site(bp):

178859953

End Site(bp):

178888122

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC008982.1	chr19	38817471	38840178	-
AC009690.3	chr15	72266746	72319946	-
AC093668.1	chr7	102541501	102592444	-
ACAD9	chr3	128879596	128916067	+
ACLY	chr17	41866917	41930542	-
ACSF3	chr16	89088375	89164121	+
ACTB	chr7	5527148	5563784	-
ACTR1A	chr10	102461881	102502712	-
ADAM15	chr1	155050566	155062775	+
ADAM19	chr5	157395534	157575775	-
ADARB1	chr21	45073853	45226560	+
ADD2	chr2	70607618	70768225	-
ADSL	chr22	40346500	40390463	+
AHCY	chr20	34280268	34311802	-
AHCYL1	chr1	109984765	110023742	+
AIF1L	chr9	131096476	131123152	+
AKAP13	chr15	85380571	85749358	+
AKT2	chr19	40230317	40285536	-
AL021546.1	chr12	120438198	120460006	+
AL022238.4	chr22	40346529	40410054	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-4517	chr16	28958587	28958611	+

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC002470.2	chr22	20979462	20998121	+
AC005899.4	chr17	32328441	32329395	+
AC007952.4	chr17	19112000	19112636	-
AC011445.1	chr19	39314651	39320858	-
AC067930.1	chr8	143579636	143580670	+
AC084082.1	chr8	66112667	66126632	+
AC144548.1	chr12	110387463	110445548	-
AC245014.3	chr1	145281116	145281462	+
AD000090.1	chr19	35557956	35581954	+
AL117378.1	chr6	131901963	131920565	+
AL132780.1	chr14	22929607	22956374	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference